Showing results (61-70 of 112) with videos related to

Sort By:
Pageof 12
Frontiers in Molecular Biosciences|February 13, 2025
Individual-network based predictions of microbial interaction signatures for response to biological therapies in IBD patientsFederico Melograna, Padhmanand Sudhakar, Behnam Yousefi, et al.
The American Journal of Gastroenterology|July 12, 2019
Prucalopride in Gastroparesis: A Randomized Placebo-Controlled Crossover StudyFlorencia Carbone, Karen Van den Houte, Egbert Clevers, et al.
Neurogastroenterology and Motility|January 28, 2026
Dose-Dependent Effect of the Histamine 1 Receptor Antagonist Ebastine in Patients With Non-Constipated Irritable Bowel SyndromeFedrica Pia, Lisse Decraecker, Danny De Looze, et al.
Journal of Crohn'S & Colitis|February 6, 2018
Long-term Outcome of Early Combined Immunosuppression Versus Conventional Management in Newly Diagnosed Crohn's DiseaseDaniël R Hoekman, Judith A Stibbe, Filip J Baert, et al.
Oncotarget|February 2, 2017
MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factorSean Caenepeel, Keegan Cooke, Sarah Wadsworth, et al.
Blood Reviews|March 25, 2020
Targeting MCL-1 in hematologic malignancies: Rationale and progressAndrew H Wei, Andrew W Roberts, Andrew Spencer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptorsAngela Coxon, Tammy Bush, Douglas Saffran, et al.
Journal of Crohn'S & Colitis|December 22, 2010
Maintenance therapy for ulcerative colitis has no impact on changes in the extent of ulcerative colitisN Eleftheriadis, G Lambrecht, G D'Haens, et al.
Pageof 12